Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr1.91 SEK
Change Today -0.01 / -0.52%
Volume 38.5K
As of 7:02 AM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).

bioinvent international ab (BINV) Snapshot

Open
kr1.88
Previous Close
kr1.92
Day High
kr1.95
Day Low
kr1.88
52 Week High
09/16/14 - kr3.03
52 Week Low
03/23/15 - kr1.72
Market Cap
311.2M
Average Volume 10 Days
221.9K
EPS TTM
kr-0.44
Shares Outstanding
112.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOINVENT INTERNATIONAL AB (BINV)

Related News

No related news articles were found.

bioinvent international ab (BINV) Related Businessweek News

No Related Businessweek News Found

bioinvent international ab (BINV) Details

BioInvent International AB (publ), a research-based pharmaceutical company, focuses on the discovery and development of antibody-based drugs against cancer. The company’s products under development include BI-505, a human antibody that is in Phase II clinical trial for the treatment of multiple myeloma; BI-1206, an antagonistic antibody aimed at the immunosuppressive target protein Fc gamma receptor IIB, CD32b, which is overexpressed on tumour cells in patients with lymphoma; and TB-403, an antibody, which is in Phase I clinical trial for the treatment of medulloblastoma. It has research collaborations with external partners, such as Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Servier, Xoma, and the University of Southampton. The Company was founded in 1997 and is based in Lund, Sweden.

39 Employees
Last Reported Date: 04/22/15
Founded in 1997

bioinvent international ab (BINV) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr735.0K
Compensation as of Fiscal Year 2013.

bioinvent international ab (BINV) Key Developments

Bioinvent International AB Reports Consolidated and Parent Earnings Results for the First Quarter Ended March 31, 2015

BioInvent International AB reported consolidated and parent earnings results for the first quarter ended March 31, 2015. For the quarter, on consolidated basis, the company reported net sales of SEK 615,000 compared to SEK 1,764,000 a year ago. Operating loss was SEK 21,800,000 compared to SEK 19,086,000 a year ago. Loss before tax was SEK 21,757,000 compared to SEK 18,933,000 a year ago. Loss was SEK 21,757,000 compared to SEK 18,933,000 a year ago. Basic and diluted EPS was SEK 0.19 compared to SEK 0.22 a year ago. Cash used in current operations was SEK 19,880,000 compared to SEK 22,969,000 a year ago. For the quarter, on parent basis, the company reported net sales of SEK 615,000 compared to SEK 1,764,000 a year ago. Operating loss was SEK 21,800,000 compared to SEK 19,086,000 a year ago. Loss after financial items was SEK 21,757,000 compared to SEK 18,933,000 a year ago. Loss was SEK 21,757,000 compared to SEK 18,933,000 a year ago.

BioInvent International and Cancer Research Technology Ltd Sign Two-Year Research Collaboration with University of Southampton

BioInvent International and Cancer Research Technology Ltd. (CRT) have signed two-year research collaboration with the University of Southampton. The program aims to develop new immunotherapy treatments for cancer based on preclinical work by the Southampton group showing the potential to treat cancer using antibodies targeting OX40 and 4-1BB - known 'co-receptors' that help stimulate the production of killer T-cells during an immune response. One of the ways that tumour cells avoid detection is by suppressing immune responses to stop functional tumour specific T-cells from being produced. The team aims to develop antibodies that can reverse this process to stimulate the immune system to fight the cancer. Terms of the collaboration were not disclosed, however, BioInvent has the option to take out a license to commercialize any promising results, with the parties receiving milestone payments and a share of potential revenues. The first phase of the project aims to identify and then validate the effectiveness of the best class of antibodies to target OX40 and 4-1BB. This work will be carried out in Lund, Sweden, and Southampton, UK, using highly specialised assays and expertise developed through a prior long-standing collaboration between BioInvent and the University of Southampton.

Bioinvent International AB Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

BioInvent International AB reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported net sales of SEK 1,672,000 compared to SEK 49,984,000 a year ago. Operating loss was SEK 28,692,000 compared to operating profit of SEK 19,905,000 a year ago. Loss after tax was SEK 28,468,000 compared to profit after tax of SEK 20,463,000 a year ago. Loss per share before and after dilution was SEK 0.25 compared to earnings per share before and after dilution of SEK 0.24 a year ago. Cash outflow from current operations was SEK 24,610,000 compared to cash inflow from current operations of SEK 24,803,000 a year ago. Acquisition of tangible fixed assets was SEK 157,000. For the year, the company reported net sales of SEK 46,932,000 compared to SEK 81,713,000 a year ago. Operating loss was SEK 54,925,000 compared to SEK 19,176,000 a year ago. Loss after tax was SEK 53,985,000 compared to SEK 18,039,000 a year ago. Loss per share before and after dilution was SEK 0.53 compared to SEK 0.23 a year ago. Cash outflow from current operations was SEK 76,028,000 compared to SEK 54,652,000 a year ago. Acquisition of tangible fixed assets was SEK 414,000 compared to SEK 47,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BINV:SS kr1.91 SEK -0.01

BINV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.85 EUR -0.05
arGEN-X BV €9.12 EUR -0.03
Genmab A/S kr514.00 DKK 0.00
ImmunoGen Inc $8.39 USD +0.12
XOMA Corp $3.26 USD +0.26
View Industry Companies
 

Industry Analysis

BINV

Industry Average

Valuation BINV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.9x
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOINVENT INTERNATIONAL AB, please visit www.bioinvent.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.